Stryker Corporation combines a near-perfect financial quality score with 13% analyst upside potential from $308, but a confirmed technical downtrend marked by a death cross and price below the 200-day moving average represents a meaningful timing risk that investors must weigh before establishing or adding to a position.
Thesis pillars
- Top Tier Financial Quality→Stable
- Analyst Upside Consensus Target↓Deteriorating
- Confirmed Technical Downtrend→Stable
- +1 more pillar — see the Why tab for full reasoning
Stryker Corporation (SYK) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $339.21, but acceptable to hold if already in. Reasons: Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers.
Stryker manufactures and sells medical devices and technologies across two segments: MedSurg and Neurotechnology ($15.6 billion, 62% of net sales) and Orthopaedics ($9.5 billion, 38%), with products sold in approximately 61 countries. The company reported $25.1 billion in total... Read more
Hold if already holding. Not a fresh buy at $339.21, but acceptable to hold if already in. Reasons: Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers. Chart setup: RSI 51 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About Stryker Corporation
About Stryker Corporation
Stryker generated $25.1 billion in net sales in 2025, split between the MedSurg and Neurotechnology segment at $15.6 billion (62%) and the Orthopaedics segment at $9.5 billion (38%), with products sold in approximately 61 countries. The Mako SmartRobotics platform is deployed in more than 45 countries, and more than two million cumulative robotic procedures have been performed globally across total knee, total hip, and partial knee applications. The company employed approximately 56,000 people globally at December 31, 2025.
Stryker sells medical devices directly to hospitals and healthcare facilities, with indirect distribution channels used in markets where direct access is limited. Within MedSurg and Neurotechnology, Medical contributed $4.2 billion (27% of the segment), Endoscopy $3.8 billion (24%), Instruments $3.2 billion (20%), Neuro Cranial $2.5 billion (16%), and Vascular $2.0 billion (13%) in 2025. Within Orthopaedics, Trauma and Extremities led at $3.9 billion (42%), followed by Knees at $2.7 billion (28%) and Hips at $1.9 billion (20%). Competitors in Instruments include Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, and ConMed Linvatec; in joint replacement, Stryker competes with Zimmer, Johnson & Johnson MedTech, and Smith & Nephew. Certain raw materials, components, and finished devices are procured from sole-source suppliers due to quality, intellectual property, and regulatory validation requirements, which may expose the company to product shortages if those suppliers face disruptions. Stryker acquired Inari Medical in 2025, integrating it into the Vascular business unit.
Show full overview
Stryker's products are subject to the European Union Medical Device Regulation, which imposes stricter clinical, quality, and post-market surveillance requirements with staggered compliance deadlines ranging from May 2026 through December 2028 depending on device type. China has implemented a volume-based procurement process for medical devices that has increased pricing pressure in that market. Tariffs enacted by the United States government and potential retaliatory measures by trading partners may further constrain supply chain availability. In May 2026, Stryker disclosed via Form 8-K that Vice President and Chief Accounting Officer William E. Berry Jr. will retire effective September 1, 2026, with Emily Baculik, current Corporate Controller, named as successor Chief Accounting Officer.
See also: Healthcare · Medical Devices
From Stryker Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-15Recent Developments — Stryker Corporation
Latest news
- NEWS Stryker (NYSE:SYK) Sets New 12-Month Low - Time to Sell? - MarketBeat — MarketBeat negative
- NEWS M&T Bank Corp Lowers Stake in Stryker Corporation $SYK - MarketBeat — MarketBeat neutral
- NEWS Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement - PR Newsw — PR Newswire neutral
- NEWS Top stock reports for Qualcomm, Intuitive Surgical & Stryker - MSN — MSN positive
- NEWS Top Stock Reports for Qualcomm, Intuitive Surgical & Stryker - Yahoo Finance — Yahoo Finance neutral
Generated 2026-08-15T11:27:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMedSurg and Neurotechnology62%10-K Item 1: 'MedSurg and Neurotechnology | $15,647 | 62%'
- HIGHSuppliersole-source suppliers10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to...quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements'
Material Events(8-K, last 90d)
- 2026-05-20Item 5.02MEDIUMVP and Chief Accounting Officer William E. Berry Jr. to retire effective September 1, 2026. Emily Baculik, current VP/Corporate Controller, named as successor Chief Accounting Officer effective the same date.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $339.21, but acceptable to hold if already in. Reasons: Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers. Chart setup: RSI 51 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $343.83 (+1.4%), stop $317.13 (−7.0%), A.R:R 0.1:1. Score 5.7/10, moderate confidence.
Take-profit target: $343.83 (+1.4% upside). Target $343.83 (+1.4%), stop $317.13 (−7.0%), A.R:R 0.1:1. Stop-loss: $317.13.
Concentration risk — Product: MedSurg and Neurotechnology (62.0%); Concentration risk — Supplier: sole-source suppliers; Analyst target reached - limited upside remaining.
Stryker Corporation trades at a P/E of 36.0 (forward 20.3). TrendMatrix value score: 4.7/10. Verdict: Hold.
34 analysts cover SYK with a consensus score of 4.2/5. Average price target: $382.
What does Stryker Corporation do?Stryker manufactures and sells medical devices and technologies across two segments: MedSurg and Neurotechnology ($15.6...
Stryker manufactures and sells medical devices and technologies across two segments: MedSurg and Neurotechnology ($15.6 billion, 62% of net sales) and Orthopaedics ($9.5 billion, 38%), with products sold in approximately 61 countries. The company reported $25.1 billion in total net sales for 2025, employing approximately 56,000 people globally. Mako SmartRobotics for joint replacement is available in more than 45 countries, with over two million robotic procedures performed to date.